as on September 15, 2025 at 10:41 pm IST
Day's Low
4.88%
Downside
52 Week's Low
52 Week's High
23.13%
Downside
400.00%
Upside
Check Gt Biopharma Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$2.9M
EPS (TTM)
-1.31
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
0P/B Ratio
0PEG Ratio
0EBITDA
-6.8M
Revenue (TTM)
-
Profit Margin
0.00%
Return On Equity TTM
668800.00%
Compare market cap, revenue, PE, and other key metrics of Gt Biopharma Inc with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
---|---|---|---|---|---|
BUY | $2.9M | 373.53% | NA | 0.00% | |
BUY | $61.1B | 256.98% | -505.15 | -12.96% | |
NA | $38.7B | NA | NA | -3.89% | |
BUY | $101.1B | 47.85% | 28.07 | 31.86% | |
BUY | $59.4B | -3.43% | 14.11 | 31.37% |
The Gt Biopharma Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Gt Biopharma Inc investment value today
Current value as on today
₹42,600
Returns
Returns from Gt Biopharma Inc Stock
Dollar Returns*
₹4,985 (+4.99%)
Based on 7 analysts
85.71%
Buy
14.29%
Hold
0.00%
Sell
Based on 7 analysts, 85.71% of analysts recommend a 'BUY' rating for Gt Biopharma Inc. Average target price of $11
Get share price movements and forecasts by analysts on Gt Biopharma Inc.
What analysts predicted
92.55%UPSIDE
Target Price
$11
Current Price
$0.82
Analyzed by
7 Analysts
Target
$11.00
Gt Biopharma Inc target price $11, a slight upside of 92.55% compared to current price of $0.82. According to 7 analysts rating.
Search interest for Gt Biopharma Inc Stock has increased by 34% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:34% versus previous 30 day period
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 123.5% return, outperforming this stock by 222.2%
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 75.6% return, outperforming this stock by 138.7%
Price Dip
In the last 7 days, GTBP stock has moved down by -6.6%
Organisation | Gt Biopharma Inc |
Headquarters | 315 Montgomery Street, San Francisco, CA, United States, 94104 |
Industry | Pharmaceuticals: Other |
CEO | Mr. Michael Martin Breen L.L.B. |
E-voting on shares | Click here to vote |
Name | Title |
---|---|
Mr. Michael Martin Breen L.L.B. | CEO & Executive Chairman |
Mr. Alan Louis Urban CPA | CFO & Secretary |
Gt Biopharma Inc share price today is $0.82 as on . Gt Biopharma Inc share today touched a day high of $0.82 and a low of $0.78.
Gt Biopharma Inc share touched a 52 week high of $4.1 on and a 52 week low of $0.63 on . Gt Biopharma Inc stock price today i.e. is trending at $0.82,which is 80.00% down from its 52 week high and 30.10% up from its 52 week low.
Gt Biopharma Inc market capitalisation is $0.00T as on .
Indian investors can start investing in Gt Biopharma Inc (GTBP) shares with as little as ₹88.141 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹881.41 in Gt Biopharma Inc stock (as per the Rupee-Dollar exchange rate as on ).
Based on Gt Biopharma Inc share’s latest price of $0.82 as on September 15, 2025 at 10:41 pm IST, you will get 12.1951 shares of Gt Biopharma Inc. Learn more about
fractional shares .
Gt Biopharma Inc stock has given 373.53% share price returns and 20.01% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?